Stonebrook Private Inc. Acquires 70 Shares of Eli Lilly and Company (NYSE:LLY)

Stonebrook Private Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 2.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,650 shares of the company’s stock after purchasing an additional 70 shares during the period. Stonebrook Private Inc.’s holdings in Eli Lilly and Company were worth $2,399,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. increased its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter worth $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter worth $36,000. Finally, Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth $37,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 1.1 %

Shares of NYSE:LLY traded down $10.04 during trading on Friday, hitting $902.71. 3,439,999 shares of the company were exchanged, compared to its average volume of 3,063,074. The stock has a market cap of $857.94 billion, a price-to-earnings ratio of 132.95, a P/E/G ratio of 2.91 and a beta of 0.41. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The firm has a fifty day moving average price of $895.97 and a two-hundred day moving average price of $827.49. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts anticipate that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 75,510 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $860.78, for a total transaction of $64,997,497.80. Following the transaction, the insider now owns 97,793,810 shares of the company’s stock, valued at $84,178,955,771.80. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last ninety days, insiders sold 737,410 shares of company stock worth $669,719,100. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Barclays increased their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Truist Financial reissued a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.